34results about How to "Improved surgical outcome" patented technology

A two-part accommodating intraocular lens (IOL) device for implantation in a capsular bag of a patient's eye. The IOL device includes a primary lens assembly and a power changing lens. The primary lens assembly includes a fixed lens and a peripherally disposed centration member. The centration member has a circumferential distal edge and a first coupling surface adjacent the circumferential distal edge. The power changing lens has an enclosed, fluid- or gel-filled lens cavity and haptic system disposed peripherally of the lens cavity. The haptic system has a peripheral engaging edge configured to contact the capsular bag and a second coupling surface. The first and second coupling surfaces are in sliding contact with one another to permit movement of the power changing lens relative to the primary lens assembly and also to maintain a spaced relationship between the fixed lens and the lens cavity during radial compression of the power changing lens.

Fastening devices are provided that are designed to effectively close tissue as well as instruments for applying the inventive fastening devices. The devices are useful for closing tissue such as mucosa in the oral cavity, oropharynx, hypopharynx, laryngeal surfaces, oronasopharynx, or other mucosal tissues. In particular, uvulopalatopharyngoplasty (UPPP), uvulopalatal flap (UPF) technique, and tonsillectomy can be assisted using the inventive system. Embodiments also provide methods of using the fastening devices and / or instruments, and kits including the fastening devices.

Provided herein are compositions and methods for treating a subject with damaged tissue, such as an injury associated with a tissue to tissue (e.g., a connective tissue-to-connective tissue or tissue to bone) interface. One aspect provides an adhesive film or adhesive layer, optionally comprising a biomaterial, tissue growth factors, including CTGF / CCN2, or cells.

It has been discovered that the 2-carbon-modified derivatives of 1α,25-dihydroxyvitamin D3 specifically stimulate osteoblasts to form new bone. The ability of the 2-carbon-modified vitamin D analogs to stimulate new bone formation suggest that these compounds can be used where synthesis of new bone is required. Thus, these compounds can be used either systemically or locally to stimulate the growth of bone transplants, to increase the rate of fracture healing and thereby reduce the time required for the healing of fractures, the stimulation of bone growth when required for replacement surgery, and also for the growth of bone to implants or other devices required to maintain the skeleton or teeth in the proper positions.